title: Detection of autoantibodies to survivin in cervical mucus from patients with human papillomavirus-associated cervical cancer and precursor lesions.
abstract: OBJECTIVE
  To investigate the prevalence of mucosal autoantibodies to survivin in patients with human papillomavirus (HPV)-associated cervical cancer and precursor lesions.
  
  
  METHODS
  Cervical mucus from 117 HPV-associated cervical cancer, 102 high-grade squamous intraepithelial lesion (HSIL), 107 low-grade SIL (LSIL), and 80 normal controls were tested by ELISA using either full length recombinant survivin or survivin-derived peptides. Survivin expression in cervical tissue biopsies was studied by Western Blotting.
  
  
  RESULTS
  Cervical mucus from 33 cervical cancer (28.2%), 17 HSIL (16.6%), and 8 LSIL (7.4%) patients reacted with recombinant survivin. The IgA-class antibody response was significantly higher than that observed in the normal controls. The level of mucosal anti-survivin response was associated to the level and intensity of survivin expression in the different lesions. Finally, reactivity against a survivin Nt-derived peptide was found more frequently than reactivity against a Ct-derived peptide.
  
  
  CONCLUSIONS
  IgA-class autoantibodies against survivin are present in a substantial proportion of cervical mucus from patients with HPV-associated cervical cancer, and precursor lesions. Mucosal anti-survivin response is positively associated with the level of survivin expression and the grade of cervical lesion.
authors.affiliation: Department of Molecular Biology and Biotechnology, Institute of Biomedical Research, National University of Mexico, Circuito Escolar s/n, Ciudad Universitaria, Mexico City, CP 04510, Mexico.
authors.forename: Lizbeth Gonzalez
authors.initials: LG
authors.lastname: Jimenez
authors.forename: Maria Cristina
authors.initials: MC
authors.lastname: Aguilar
authors.forename: Olga L
authors.initials: OL
authors.lastname: Monroy
authors.forename: Fernando
authors.initials: F
authors.lastname: Cruz-Talonia
authors.forename: Rosa M
authors.initials: RM
authors.lastname: Cruz
authors.forename: Carlos
authors.initials: C
authors.lastname: Huitron
authors.forename: Leticia
authors.initials: L
authors.lastname: Rocha-Zavaleta
mesh_terms: D001323:Autoantibodies / Q000096:biosynthesis* / Q000276:immunology; D002582:Cervix Mucus / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005260:Female; D006801:Humans; D007070:Immunoglobulin A / Q000276:immunology; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins / Q000096:biosynthesis / Q000276:immunology*; D009363:Neoplasm Proteins / Q000096:biosynthesis / Q000276:immunology*; D027383:Papillomaviridae / Q000276:immunology*; D030361:Papillomavirus Infections / Q000150:complications / Q000276:immunology*; D011446:Prospective Studies; D000077022:Survivin; D002583:Uterine Cervical Neoplasms / Q000276:immunology* / Q000473:pathology / Q000821:virology; D002578:Uterine Cervical Dysplasia / Q000276:immunology* / Q000821:virology
chemical_list: D001323:Autoantibodies; C107489:BIRC5 protein, human; D007070:Immunoglobulin A; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D009363:Neoplasm Proteins; D000077022:Survivin